Metabolic syndrome and related liver diseases

Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues

Volumn , Issue , 2012, Pages 137-157

  Delgado Borrego, Aymin ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Alanine aminotransferase (ALT); Cirrhosis; Fibrosis; Liver; Liver enzymes; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Obesity; Steatosis; Vitamin E

Indexed keywords

EID: 84877288475     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-2366-8_7     Document Type: Chapter

References (132)

1. Feldstein AE, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009, 58(11):1538-44.
2. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979, 67(5):811-6.
3. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980, 55(7):434-8.
4. Moran JR, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983, 78:374-7.
5. Alisi A, et al. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr. 2009, 155(4): 469-74.
6. Loomba R, et al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009, 50(4): 1282-93.
7. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41(6):1313-21.
8. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000, 136(6):727-33.
9. Park HS, et al. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr. 2005, 82(5):1046-51.
10. Schwimmer JB, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006, 118(4): 1388-93.
11. Franzese A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997, 42(7): 1428-32.
12. Chan DF, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord. 2004, 28(10): 1257-63.
13. Tazawa Y, et al. Serum alanine aminotransferase activity in obese children. Acta Paediatr. 1997, 86(3):238-41.
14. Manton ND, et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust. 2000, 173(9):476-9.
15. Schwimmer JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003, 143(4):500-5.
16. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000, 30(1):48-53.
17. Nguyen TT, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr. 2001, 138(4):474-80.
18. Fishbein MH, et al. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr. 2003, 36(1):54-61.
19. Taylor KJ, et al. Ultrasonography of alcoholic liver disease with histological correlation. Radiology. 1981, 141(1):157-61.
20. Needleman L, et al. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. AJR Am J Roentgenol. 1986, 146(5):1011-5.
21. Mathiesen UL, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 2002, 34(7):516-22.
22. Celle G, et al. Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. Dig Dis Sci. 1988, 33(4):467-71.
23. Bydder GM, et al. Computed tomography attenuation values in fatty liver. J Comput Tomogr. 1981, 5(1):33-5.
24. Jacobs JE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol. 1998, 171(3):659-64.
25. Rinella ME, et al. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: implications for living liver donation. Liver Transpl. 2003, 9(8):851-6.
26. Fishbein MH, et al. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging. 1997, 15(3):287-93.
27. Nobili V, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008, 48(2):442-8.
28. Yoneda M, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008, 40(5):371-8.
29. Huwart L, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008, 135(1):32-40.
30. Baldridge AD, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995, 127(5):700-4.
31. Schwimmer JB, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005, 42(3):641-9.
32. Molleston JP, et al. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002, 97(9):2460-2.
33. Jonas MM, et al. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome. Liver Transpl. 2005, 11(1): 108-10.
34. Adams LA, et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004, 39(4):909-14.
35. Cuadrado A, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg. 2005, 15(3):442-6.
36. Schwimmer JB, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008, 118(3):277-83.
37. Demircioglu F, et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008, 47(1):68-75.
38. Pacifico L, et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res. 2008, 63(4):423-7.
39. Norman D, et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep. 2008, 31(1):121-6.
40. Gardner CJ, et al. Hypothyroidism in a patient with non-alcoholic fatty liver disease. BMJ. 2011, 342:c7199.
41. Lee TH, et al. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008, 47(3):880-7.
42. Schindhelm RK, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006, 22(6):437-43.
43. Di Bonito P, et al. Association of elevated serum alanine aminotransferase with metabolic factors in obese children: sex-related analysis. Metabolism. 2009, 58(3):368-72.
44. Wei C, et al. Abnormal liver function in children with metabolic syndrome from a UK-based obesity clinic. Arch Dis Child. 2011, 96:1003-7. doi:10.1136/adc.2010.190975.
45. van Vliet M, et al. The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin. Eur J Pediatr. 2009, 168(5):585-91.
46. Patel DA, et al. Serum alanine aminotransferase and its association with metabolic syndrome in children: the bogalusa heart study. Metab Syndr Relat Disord. 2011, 9(3):211-6.
47. Marchesini G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003, 37(4):917-23.
48. Fan JG, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005, 20(12):1825-32.
49. Kim HC, et al. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol. 2005, 11(34):5314-21.
50. Hamaguchi M, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005, 143(10):722-8.
51. Love-Osborne KA, et al. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. J Adolesc Health. 2008, 42(6):543-8.
52. Tominaga K, et al. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med. 2009, 14(2):142-9.
53. Kelishadi R, et al. Association of the components of the metabolic syndrome with nonalcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol Metab Syndr. 2009, 1:29.
54. Fu JF, et al. Non-alcoholic fatty liver disease: an early mediator predicting metabolic syndrome in obese children? World J Gastroenterol. 2011, 17(6):735-42.
55. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285(19):2486-97.
56. Manco M, et al. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008, 32(2):381-7.
57. Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. World J Gastroenterol. 2010, 16(42):5280-5.
58. Nobili V, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006, 44(2):458-65.
59. Patton HM, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol. 2010, 105(9):2093-102.
60. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008, 48 Suppl 1:S104-12.
61. Alisi A, et al. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med. 2011. doi:10.3109/07853890.2010.547869.
62. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346(16):1221-31.
63. Musso G, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003, 37(4):909-16.
64. Cortez-Pinto H, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999, 282(17):1659-64.
65. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis. 2009, 13(4):545-63.
66. Boden G, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 2005, 54(12):3458-65.
67. Park SH, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004, 19(6):694-8.
68. Kral JG, et al. Hepatic lipid metabolism in severe human obesity. Metabolism. 1977, 26(9): 1025-31.
69. Sanyal AJ, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001, 120(5):1183-92.
70. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr. 2009, 21(4):529-35.
71. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001, 414(6865):799-806.
72. Fleischmann M, Iynedjian PB. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J. 2000, 349(Pt 1):13-7.
73. Shimomura I, et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A. 1999, 96(24):13656-61.
74. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008, 19(10):371-9.
75. Malaguarnera M, et al. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009, 87(7):679-95.
76. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steato-hepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010, 52(2):774-88.
77. Louthan MV, et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr. 2005, 147(6):835-8.
78. Nobili V, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol. 2006, 155(5):735-43.
79. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009, 51(1):212-23.
80. O'Sullivan TA, et al. Dietary glycaemic carbohydrate in relation to the metabolic syndrome in adolescents: comparison of different metabolic syndrome definitions. Diabet Med. 2010, 27(7):770-8.
81. Aeberli I, et al. Diet determines features of the metabolic syndrome in 6- to 14-year-old children. Int J Vitam Nutr Res. 2009, 79(1):14-23.
82. Chu NF, Chang JB, Shieh SM. Plasma leptin, fatty acids, and tumor necrosis factor-receptor and insulin resistance in children. Obes Res. 2003, 11(4):532-40.
83. Turi S, et al. Oxidative stress in juvenile essential hypertension. J Hypertens. 2003, 21(1): 145-52.
84. Sinaiko AR, et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation. 2005, 111(15): 1985-91.
85. Kelly AS, et al. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr. 2006, 1(4):248-52.
86. Korner A, et al. New predictors of the metabolic syndrome in children - role of adipocytok-ines. Pediatr Res. 2007, 61(6):640-5.
87. Calcaterra V, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. Acta Biomed. 2009, 80(2):117-23.
88. Hales CN, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991, 303(6809): 1019-22.
89. Geremia C, Cianfarani S. Insulin sensitivity in children born small for gestational age (SGA). Rev Diabet Stud. 2004, 1(2):58-65.
90. Levy-Marchal C, Czernichow P. Small for gestational age and the metabolic syndrome: which mechanism is suggested by epidemiological and clinical studies? Horm Res. 2006, 65 Suppl 3:123-30.
91. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001, 60:5-20.
92. Ross MG, Beall MH. Adult sequelae of intrauterine growth restriction. Semin Perinatol. 2008, 32(3):213-8.
93. Godfrey KM, et al. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007, 61(5 Pt 2):5R-10.
94. Nobili V, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care. 2007, 30(10):2638-40.
95. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000, 108(1):9-13.
96. Willner IR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001, 96(10):2957-61.
97. Browning JD, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004, 40(6):1387-95.
98. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc. 2010, 69(2):211-20.
99. Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008, 40(12):1461-5.
100. Hoekstra M, et al. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol. 2010, 52(2):244-51.
101. Sookoian SC, Gonzalez C, Pirola CJ. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res. 2005, 13(12):2122-31.
102. Sookoian S, et al. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome. Am J Hypertens. 2005, 18(10):1271-5.
103. Vasseur F, Meyre D, Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev Mol Med. 2006, 8(27):1-12.
104. Ferguson JF, et al. Gene-nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. Am J Clin Nutr. 2010, 91(3):794-801.
105. Zak A, et al. The influence of polymorphism of -493 G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress. J Nutr Biochem. 2008, 19(9):634-41.
106. Robitaille J, et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004, 49(9):482-9.
107. Phillips CM, et al. Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults. J Nutr. 2010, 140(2):238-44.
108. Stancakova A, et al. Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physiol Res. 2006, 55(5):483-90.
109. Zhou YJ, et al. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol. 2010, 25(4):772-7.
110. Vimaleswaran KS, et al. Absence of association of metabolic syndrome with PPARGC1A, PPARG and UCP1 gene polymorphisms in Asian Indians. Metab Syndr Relat Disord. 2007, 5(2):153-62.
111. Johansson LE, et al. Genetic variance in the adiponutrin gene family and childhood obesity. PLoS One. 2009, 4(4):e5327.
112. Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr. 2009, 49(4):442-9.
113. Hossain N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009, 7(11):1224-9, 1229 e1-2.
114. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steato-hepatitis. Hepatology. 1999, 30(6):1356-62.
115. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005, 100(7): 1509-15.
116. Svegliati-Baroni G, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999, 29(6):1743-51.
117. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004, 8(3):521-33, 8.
118. Hesham AKH. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J Pediatr. 2009, 5(4):245-54.
119. Nielsen S, et al. Splanchnic lipolysis in human obesity. J Clin Invest. 2004, 113(11):1582-8.
120. Donnelly KL, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005, 115(5):1343-51.
121. Kelley DE, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003, 285(4): E906-16.
122. Uusitupa M, et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003, 52(10):2532-8.
123. Schindhelm RK, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007, 191(2):391-6.
124. Schindhelm RK, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005, 35(6):369-74.
125. Ekstedt M, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006, 44(4):865-73.
126. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr Metab Immune Disord Drug Targets. 2008, 8(4):301-7.
127. Amaral JF, Thompson WR. Gallbladder disease in the morbidly obese. Am J Surg. 1985, 149(4):551-7.
128. Baker S, et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005, 40(5):533-43.
129. Petersen KF, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005, 54(3):603-8.
130. Ebbeling CB, et al. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007, 297(19):2092-102.
131. Benjaminov O, et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc. 2007, 21(8):1423-7.
132. Lavine JE, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011, 305(16): 1659-68.